PMHNP Scope of Practice for Weight Loss/GLP-1 in Illinois

If you’re a psychiatrist or PMHNP wondering whether you can prescribe GLP-1 medications like semaglutide (Ozempic/Wegovy) or controlled weight-loss drugs like phentermine via telehealth — you’re not alone. The telehealth weight-loss market exploded after COVID, but the regulatory landscape remains confusing. Federal DEA rules are in flux, state laws vary wildly, and scope-of-practice questions complicate things for psychiatric prescribers venturing into metabolic health.

Here’s what you actually need to know to practice legally and safely in 2025-2026.

The Short Answer: Yes, But It Depends on Your State and the Medication

For GLP-1 agonists (semaglutide, tirzepatide): These are not controlled substances, so you can prescribe them via telehealth in most states as long as you meet standard telehealth exam requirements. No special DEA restrictions apply.

For controlled substances (phentermine, other appetite suppressants): The rules are messier. The DEA’s COVID-era flexibility allowing telehealth prescribing of controlled drugs has been extended through December 31, 2026 — meaning you can currently prescribe Schedule III-V controlled weight-loss medications via telemedicine nationwide without an in-person exam. But this is temporary, and some states have their own stricter rules.

The catch: Even if federal law allows it, your state may require an in-person visit for controlled substances. New York, for example, now mandates at least one face-to-face exam before prescribing any controlled medication, with narrow exceptions. Florida prohibits teleprescribing Schedule II stimulants (though phentermine is Schedule IV, so it’s allowed). Texas and California are more permissive under current law.

And if you’re a PMHNP, you face an additional layer: Is prescribing for obesity within your scope of practice? Most psychiatric nurse practitioners are trained for mental health conditions, not metabolic disease. You’ll likely need physician collaboration or additional certification to safely offer weight management.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Understanding the Federal DEA Rules (2025-2026)

The Ryan Haight Act and COVID Waivers

Pre-pandemic, the Ryan Haight Online Pharmacy Act required an in-person medical evaluation before prescribing any controlled substance via telemedicine. During COVID, that requirement was waived to maintain access to care — allowing psychiatrists to start new patients on ADHD stimulants, anxiety meds, and weight-loss drugs remotely.

Current status: The DEA and HHS extended these flexibilities through the end of 2026 to prevent a ‘telehealth cliff’ while permanent rules are developed. This means you can continue prescribing controlled substances (including phentermine for weight loss) via telehealth without an initial in-person visit — at least federally — until December 31, 2026.

What’s coming: The DEA is developing new permanent regulations, likely requiring either a special telemedicine registration or imposing limits (like initial 30-day supplies for certain Schedule II drugs). They’ve proposed allowing certain specialists to prescribe Schedule II controlled substances via telehealth with restrictions — possibly requiring the provider and patient to be in the same state and capping tele-prescriptions as a percentage of total practice. Public comment periods closed in early 2025; final rules are pending.

For weight-loss prescribers: GLP-1 drugs sidestep all of this — they’re not controlled, so Ryan Haight doesn’t apply. Phentermine (Schedule IV) remains legal to prescribe via telehealth under the current federal extension, but you must still comply with state PDMP (Prescription Drug Monitoring Program) requirements and maintain a valid DEA registration.

State Rules: Where It Gets Complicated

States That Require In-Person Exams for Controlled Substances

New York is the strictest. As of May 2025, New York regulations require at least one in-person medical evaluation before prescribing any controlled substance. The only exceptions:

• A consulting provider examined the patient in-person within the past 12 months and shared records
• You’re covering for a colleague who saw the patient face-to-face
• It’s an emergency for an existing patient (max 5-day supply)

Practical impact: If you’re treating a New York patient via telehealth and want to prescribe phentermine, you’ll need to see them in person first (or coordinate with a local provider who can). For GLP-1s like semaglutide, you’re fine — no in-person requirement for non-controlled meds.

New York also mandates checking the state’s Prescription Monitoring Program within 24 hours before issuing any Schedule II-IV prescription, and all prescriptions must be e-prescribed.

States That Allow Telehealth Prescribing with Conditions

Florida has detailed rules:

• Schedule II drugs (like Adderall) cannot be prescribed via telehealth for weight loss (though they can be for psychiatric disorders — Florida carved out an exception for mental health treatment)
• Schedule III-V drugs (phentermine) are fine via telehealth
• Obesity prescribing standards apply to all providers: You must document BMI ≥30 (or ≥27 with comorbidities), obtain written informed consent outlining risks, and re-evaluate patients every 3 months minimum
• You must provide patients with Florida’s ‘Weight-Loss Consumer Bill of Rights’
• All prescribers must check Florida’s E-FORCSE PDMP before prescribing any controlled substance

Texas is relatively permissive:

• No state-level in-person exam requirement for telehealth prescribing
• You can prescribe phentermine via live video if it meets the standard of care
• Must check the Texas Prescription Monitoring Program for controlled substances
• Providers should send follow-up reports to the patient’s primary care physician within 72 hours (with patient consent)
• NPs and PAs need a Prescriptive Authority Agreement with a physician to prescribe controlled substances

California:

• Telehealth exams satisfy the ‘appropriate prior examination’ requirement
• No ban on controlled substance prescribing via telehealth
• Must obtain documented patient consent for telehealth services
• Must check CURES (CA’s PDMP) before first controlled substance prescription and every 4 months for ongoing therapy
• Strict Corporate Practice of Medicine rules — only physician-owned entities can provide medical services (relevant if you’re setting up a telehealth practice)

Pennsylvania and Illinois generally follow federal law with no additional state-level in-person requirements, though both have robust PDMP check mandates (Pennsylvania requires checks for each opioid/benzo prescription; Illinois for Schedule II narcotics).

Scope of Practice: Can Psychiatrists Prescribe Weight-Loss Meds?

For Psychiatrists (MD/DO)

Yes, legally. You hold an unrestricted medical license and can prescribe FDA-approved weight-loss medications or use GLP-1s off-label. There’s no separate ‘obesity license.’

But: You assume responsibility for practicing competently. State medical boards will hold you to the same standards as a bariatric specialist or internist treating obesity. That means:

• Documenting appropriate patient selection (BMI criteria, contraindications)
• Obtaining informed consent about risks and benefits
• Following state-specific obesity treatment protocols (like Florida’s quarterly follow-up requirement)
• Incorporating behavioral counseling on diet and exercise, or referring to specialists
• Monitoring for side effects and drug interactions (especially relevant given psychiatric medications’ metabolic effects)

The clinical angle: Many psychiatrists encounter weight management tangentially — patients gaining weight from antipsychotics, patients with binge-eating disorder, comorbid depression and obesity. Prescribing a GLP-1 to mitigate antipsychotic-induced weight gain is clinically defensible. Running a pure weight-loss telehealth business as a psychiatrist is legal but may raise eyebrows with your malpractice carrier unless you have additional training or certification in obesity medicine.

For PMHNPs

More complicated. Your scope of practice is defined by your training and certification in psychiatric-mental health, not metabolic or endocrine conditions.

Can you prescribe weight-loss meds? Technically, if you have prescriptive authority in your state and the medication is within your delegated or independent scope, you could. But:

• Most state nursing boards expect NPs to practice within their area of certification and competence
• Prescribing purely for obesity (not a psychiatric indication) may be viewed as outside your scope
• You’ll likely need physician collaboration or supervision — ideally with a physician who has appropriate expertise (family practice, internal medicine, endocrinology), not just a psychiatrist

State-specific considerations:

• California: PMHNPs practice under Standardized Procedures with physician oversight. To prescribe weight-loss drugs, you’d need a physician who’s comfortable overseeing obesity treatment. AB 890 allows experienced NPs to practice independently starting in 2026, but your independent authority would still be limited to your population focus (psych)
• Texas: PMHNPs need a Prescriptive Authority Agreement that specifically delegates weight-loss treatment. Your collaborating physician should have expertise in the area
• Florida: Psych NPs still require physician collaboration. Treating obesity would be a stretch without a family medicine or bariatric MD/DO involved
• New York: PMHNPs can practice independently after 3,600 hours, but you’d still be expected to practice within your training. Offering weight-loss services without additional certification or physician consultation could expose you to board complaints
• Illinois: Full Practice Authority is available for experienced PMHNPs, but again, scope matters. You’d be wise to coordinate with or refer to appropriate specialists

Bottom line for PMHNPs: Stick to treating psychiatric conditions. If you want to offer weight management, either get additional training/certification in obesity medicine, or structure your practice with clear physician oversight by someone qualified in metabolic health.

The Economics: Is Telehealth Weight Loss Prescribing Worth It?

Let’s talk business reality. Building a telehealth weight-loss practice from scratch means competing with established platforms and figuring out patient acquisition.

The DIY Marketing Trap

Many providers assume they can acquire weight-loss patients cheaply through Google Ads, SEO, or directory listings. The math rarely works out:

• Google Ads: Mental health and weight-loss keywords cost $15-40+ per click. Most clicks don’t convert to booked patients. A realistic cost per booked appointment through PPC is $200-400+ after accounting for ad spend, failed campaigns, and no-shows from cold leads
• SEO: Takes 6-12 months of consistent investment (content, backlinks, technical optimization) before generating meaningful patient flow. Most solo providers don’t have the expertise, budget, or patience
• Psychology Today / Zocdoc: Monthly subscription fees plus intense competition on the same listings. Zocdoc charges $35-100+ per booking, and you’re competing with hundreds of other providers. Total monthly cost including subscription easily reaches $500-1,000+ for uncertain volume

Real acquisition costs: When you factor in agency/consultant fees, staff time to qualify leads, no-show rates, and months of testing before channels work, acquiring a qualified psychiatric or weight-loss patient through DIY marketing typically costs $200-500+ per patient. Many providers burn $3,000-5,000/month on marketing with uncertain ROI.

The Platform Alternative

This is where platforms like Klarity Health make economic sense. Instead of gambling on marketing channels, you pay a standard listing fee per new patient lead — only when a qualified patient actually books with you.

Key advantages:

• No upfront marketing spend or monthly subscriptions
• Pre-qualified patients already matched to your specialty and availability
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure (no separate platform costs for video, EHR, etc.)
• Both insurance and cash-pay patient flow
• You control your schedule — only pay when you see patients

The ROI calculation: Instead of spending $3,000-5,000/month on uncertain marketing, you pay per appointment. That’s guaranteed ROI. You know your acquisition cost upfront, you avoid the months of trial-and-error in marketing, and you can scale patient volume without scaling risk.

This model works especially well for providers starting out, scaling an existing practice, or entering new markets (like weight loss if you’re primarily a psychiatrist). The platform removes patient acquisition risk entirely.

Ensuring Compliance: Best Practices Across All States

Regardless of where you practice, follow these universal protocols:

1. Verify Patient Location and Your Licensure

You must be licensed in the state where the patient is physically located during the telehealth visit. Verify location at each appointment — patients travel. If you’re treating patients in multiple states, obtain licenses in each (or use the Interstate Medical Licensure Compact if your state participates).

2. Conduct a Proper Telehealth Exam

State medical boards review telehealth cases to ensure documentation shows an adequate evaluation. Your notes should include:

• Patient history and chief complaint
• Review of systems relevant to weight loss (cardiovascular, endocrine, psychiatric)
• Vital signs if obtainable (weight, BMI, blood pressure)
• Mental status exam (for psych) or physical exam elements (for weight loss)
• Discussion of risks, benefits, and alternatives
• Documentation of informed consent

Most states require synchronous audio-video interaction for initial prescriptions. Online questionnaires alone are insufficient.

3. Follow State-Specific Prescribing Protocols

For controlled substances:

• Check your state’s PDMP before prescribing (e.g., California requires CURES checks every 4 months; Pennsylvania requires checks for each opioid/benzo prescription; New York within 24 hours before prescribing)
• Use e-prescribing (mandatory in New York, Illinois, California, and most other states for controlled substances)
• Document clinical justification and follow-up plans

For weight-loss treatment (Florida example):

• Document BMI and comorbidities
• Obtain written informed consent
• Schedule follow-ups every 3 months minimum
• Provide required consumer disclosures

4. Coordinate with Primary Care

Many states expect you to communicate with the patient’s primary care provider when treating conditions outside your specialty. Texas law requires sending follow-up reports within 72 hours (with patient consent). Even where not legally required, coordination improves patient safety and shows good faith if your care is ever questioned.

New Jersey explicitly requires psychiatric evaluation before prescribing weight-loss drugs — a recognition that depression, eating disorders, or other mental health issues should be addressed for safe treatment. This is an area where psychiatrists can add real value in an interdisciplinary approach.

5. Use Secure, HIPAA-Compliant Platforms

State telehealth laws require equivalent privacy protections as in-person care. Use encrypted video platforms, secure messaging, and proper data storage. Document patient consent for telehealth services where required (California, Illinois, and others mandate this).

State-by-State Prescribing Summary

The Bottom Line

Can psychiatrists prescribe weight-loss medications via telehealth? Yes, with careful attention to state rules and scope of practice.

For GLP-1 agonists: You’re in clear legal territory in most states. Ensure you conduct a proper telehealth exam, document appropriately, and follow standard obesity treatment protocols.

For controlled substances: You can prescribe through 2026 under the federal DEA extension, but check your state’s specific requirements. New York effectively prohibits it without an in-person exam; most other states allow it with proper documentation and PDMP checks.

For PMHNPs: Proceed cautiously. Treating obesity may be outside your scope unless you have physician collaboration or additional training. Focus on psychiatric conditions where you have clear authority, or structure your practice with appropriate medical oversight.

On patient acquisition: Building a telehealth practice through DIY marketing is expensive and uncertain. Platforms that handle patient acquisition on a pay-per-appointment model remove the risk and let you focus on clinical care rather than marketing trial-and-error.

The regulatory landscape is evolving. Federal DEA rules will change by 2027. State telehealth laws continue to develop. Stay current by monitoring your state medical board announcements, subscribing to telehealth policy updates (organizations like CCHP track state laws), and consulting healthcare attorneys when launching new service lines.

If you’re a psychiatrist looking to expand into weight management or a PMHNP considering obesity treatment, the legal pathway exists — but it requires compliance diligence and, often, the right infrastructure to acquire patients and deliver care efficiently.

Frequently Asked Questions

Can I prescribe semaglutide (Ozempic/Wegovy) via telehealth without seeing the patient in person?

Yes, in most states. GLP-1 agonists are not controlled substances, so the DEA’s in-person exam requirement doesn’t apply. You must conduct a proper telehealth evaluation (usually via video) that meets your state’s standard of care, document the patient’s BMI and medical history, and obtain informed consent. States like Florida require specific obesity treatment protocols (written consent, quarterly follow-ups), so check your state’s medical board rules.

Do I need an in-person visit to prescribe phentermine online?

Under current federal law (DEA extension through Dec 31, 2026), no in-person visit is required. However, state law may be stricter. New York requires at least one in-person exam before prescribing any controlled substance via telehealth. Texas, California, Florida, Pennsylvania, and Illinois allow telehealth prescribing of phentermine (Schedule IV) under the current federal waiver, as long as you meet state telemedicine standards (proper exam, PDMP checks, documentation).

As a PMHNP, can I legally offer weight-loss treatment?

It depends on your state’s scope-of-practice rules and whether you have physician oversight. Your training is in psychiatric-mental health, so prescribing purely for obesity may be viewed as outside your scope. States like Texas and California require NPs to practice under physician protocols or supervision unless you have independent practice authority — and even then, you’re expected to stay within your area of competence. If you want to offer weight management, either obtain additional certification in obesity medicine or partner with a physician who has appropriate expertise (family medicine, internal medicine, endocrinology).

Which states have the strictest telehealth prescribing rules?

New York is the strictest for controlled substances — requiring an in-person exam before prescribing any controlled medication via telehealth, with very limited exceptions. Florida prohibits teleprescribing Schedule II drugs for non-psychiatric conditions and imposes detailed obesity treatment standards. California has strict Corporate Practice of Medicine rules affecting how you structure a telehealth practice. Most other states defer to federal law and professional standards, making them more permissive.

Do I need to check the state Prescription Drug Monitoring Program (PDMP) before prescribing weight-loss drugs?

For controlled substances (like phentermine), yes. Every state with a PDMP requires checking it before prescribing controlled medications, though the specific timing varies:

• California: Before first prescription and every 4 months for ongoing therapy
• New York: Within 24 hours before prescribing any Schedule II-IV drug
• Pennsylvania: Before each opioid/benzodiazepine prescription
• Texas: Before prescribing certain controlled substances (opioids, benzos, barbiturates)

For non-controlled GLP-1s, PDMP checks aren’t legally required, but best practice suggests reviewing the patient’s medication history to identify potential drug interactions or duplicative therapy.

What are the real costs of acquiring weight-loss patients through digital marketing?

Acquiring qualified patients through DIY marketing typically costs $200-500+ per patient when you account for all expenses:

• Google Ads: $15-40+ per click for weight-loss keywords; most clicks don’t convert
• SEO: 6-12 months of investment before meaningful results
• Directory listings: $35-100+ per booking on platforms like Zocdoc, plus monthly subscription fees
• Agency/consultant fees for managing campaigns
• Staff time to qualify leads and handle no-shows

Most solo providers spend $3,000-5,000/month on marketing with uncertain ROI before channels start producing consistent patient flow. Platform-based models that charge per booked appointment remove this risk by offering predictable acquisition costs.

How do I structure a weight-loss telehealth practice to stay compliant?

Follow these steps:

1. Obtain licenses in every state where you’ll treat patients
2. Verify your scope — psychiatrists can prescribe weight-loss meds legally; PMHNPs may need physician collaboration
3. Implement proper protocols: initial evaluation checklist, informed consent documentation, follow-up schedules
4. Use HIPAA-compliant telehealth platforms with encrypted video
5. Check PDMPs and use e-prescribing for controlled substances
6. Follow state-specific rules: Florida’s quarterly follow-ups, California’s telehealth consent, New York’s in-person exam requirement for controlled substances
7. Coordinate with primary care and document all clinical decisions
8. Consider malpractice insurance that covers telehealth and weight management if outside your primary specialty

If you’re structuring a multi-provider practice, be aware of Corporate Practice of Medicine rules (especially in California and Texas) that may require physician ownership or specific management agreements.

Ready to Start Treating Weight-Loss Patients via Telehealth?

The regulatory pathway is complex, but the opportunity is real. Weight management is one of the fastest-growing telehealth specialties, and psychiatric providers have unique insights into the behavioral and mental health aspects of obesity treatment.

If patient acquisition and compliance infrastructure feel overwhelming, consider joining a platform that handles the heavy lifting. Klarity Health connects providers with pre-qualified patients seeking weight management and psychiatric care, handles patient acquisition on a pay-per-appointment model, and provides built-in telehealth tools and support.

You focus on clinical care. We handle everything else.

Explore joining Klarity’s provider network →

Citations and References

1. U.S. Department of Health & Human Services. (2026, January 2). HHS & DEA extend telemedicine flexibilities for prescribing controlled medications through 2026. https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. Florida Statutes § 456.47. (2019). Use of telehealth to provide services (Florida Telehealth Act). http://www.leg.state.fl.us/statutes/

3. Florida Administrative Code 64B8-9.012. (2022, August 8). Standards for the prescription of drugs to treat obesity. https://regulations.justia.com/states/florida/64/64b8/chapter-64b8-9/section-64b8-9-012/

4. Goodwin Procter LLP. (2024, March 30). A changing regulatory and reimbursement landscape for weight-loss drugs. https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs

5. McDermott Will & Emery. (2023, September 29). Weight-loss programs in Florida: State law considerations for GLP-1 telehealth providers. https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/

6. Medical Director Compliance Consulting. (2025). California weight loss clinic & telehealth compliance guide (2025). https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/

7. Medical Director Compliance Consulting. (2025). Texas weight loss clinic & telehealth compliance guide. https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/

8. New York Codes, Rules & Regulations Title 10, § 80.63. (2025, May). Prescribing of controlled substances. https://www.law.cornell.edu/regulations/new-york/10-NYCRR-80.63

9. Landi, H. (2025, February 13). Primary care doctors concerned about telehealth GLP-1 boom: Survey. Fierce Healthcare. https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey

10. California Medical Association. (2025, December 2). GLP-1 medications for weight loss will no longer be covered by Medi-Cal. https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal

11. Center for Connected Health Policy. (2025, November 21). State telehealth policies for online prescribing. https://www.cchpca.org/topic/online-prescribing/

12. Pennsylvania Department of Health. (2022). Prescription Drug Monitoring Program FAQs. https://www.pa.gov/agencies/health/programs/opioids/prescribers-and-providers/prescribing-guidelines.html

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,disruptions%20in%20care%20while%20permanent
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,FDA%2C%20pharmacy%2C%20and%20board%20alerts
• https://www.cchpca.org/topic/online-prescribing/#:~:text=No%20controlled%20substance%20shall%20be,for%20the%20medical%20evaluation%2C%20and
• https://florida.public.law/statutes/fla.stat.456.47#:~:text=provider%20is%20not%20required%20to,is%20prescribed%20for%20the%20following
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=Florida%20law%20restricts%20the%20prescribing,5
• https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/#:~:text=2000%20%28Fla,loss%20providers%20are%20required%20to
• https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/#:~:text=medical%20director%20and%20retain%20full,Clinics%20must%20maintain%20DEA
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,require%20DEA%20registration
• https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey#:~:text=Primary%20care%20physicians%20are%20mainly,cited%20by%20half%20of%20physicians
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated